Boston Scientific Corp (BSX) 22.37 $BSX
Genomic Health: Can the Liquid Biopsy Test Boost Margins?
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:50AM CDT
Genomic Health (GHDX) recently launched a next-generation sequencing blood-based mutational panel -- Oncotype SEQ Liquid Select.
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), GHDX: 26.11 (-0.48)
GNC Gains as Buyout Rumors of Vitamin Shoppe Resurface
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:32AM CDT
The Vitamin Shoppe buyout rumor first buzzed in immediately after GNC Holdings Inc.'s (GNC) earnings call in the last quarter.
BSX: 22.37 (-0.60), HLF: 57.50 (-4.83), BAX: 43.85 (-2.11), GNC: 24.50 (-1.22)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), QGEN: 21.01 (-1.38)
27.0% Return Seen to Date on SmarTrend Boston Scientific Call (BSX)
Comtex SmarTrend(R) - Mon Jun 20, 1:24PM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on March 14th, 2016 at $18.01. In approximately 3 months, Boston Scientific has returned 27.02% as of today's recent price of $22.87.
BSX: 22.37 (-0.60)
Xtant(TM) Medical Announces Changes to Its Executive Management and Board of Directors
GlobeNewswire - Thu Jun 16, 4:33PM CDT
Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Paul Buckman, Eric Timko, and Rudy Mazzocchi to its Board of Directors. The Company also announced the resignation of Directors Jon Wickwire and David Goodman. The above changes will be effective as of July 2, 2016.
BSX: 22.37 (-0.60), XTNT: 2.00 (-0.05)
Boston Scientific: NICE Backs GreenLight XPS for BPH Cure
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:01AM CDT
As per NICE's estimates, broad adoption of Boston Scientific's (BSX) GreenLight therapy over TURP can lead to savings of up to ??3.2 million annually for the National Health Service (NHS).
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), NUVA: 57.93 (-0.93)
Boston Scientific (BSX) Breaks Through Support at $22.85
Comtex SmarTrend(R) - Tue Jun 14, 9:07AM CDT
Shares of Boston Scientific (NYSE:BSX) have bearishly opened below the pivot of $23.00 today and have reached the first support level of $22.85. Investors may be interested in a cross of the next downside pivot targets of $22.75 and $22.50.
BSX: 22.37 (-0.60)
National Institute for Health and Care Excellence Provides Positive Guidance for Use of Boston Scientific GreenLight XPS(TM) Laser Therapy System in the Treatment of BPH
PR Newswire Europe - Tue Jun 14, 7:30AM CDT
Studies show that treatment is less costly and has lower hospital re-admissions
BSX: 22.37 (-0.60)
Boston Scientific: Restructuring Plan, Global Growth Impress
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 6:14AM CDT
On Jun 13, 2016, we issued an updated research report on Boston Scientific Corporation (BSX).
BSX: 22.37 (-0.60), ICUI: 106.49 (-1.64), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40)
The 3 Top Total Returning Mutual Funds Over The Last 3 Years
Adam Clark - Zacks Investment Research - Mon Jun 13, 3:17PM CDT
These mutual funds have produced the highest total return percentage in the last 3 years, and have the potential to remain atop the top-performing mutual fund list.
BSX: 22.37 (-0.60), ISRG: 644.82 (-16.50), TSLA: 193.15 (-3.25), AMZN: 698.96 (-23.12), MDT: 83.26 (-2.51), LBTYA: 28.80 (-4.34), FB: 112.08 (-3.00), GOOGL: 685.20 (-29.67)
Shares of BSX Up 27.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 1:14PM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on March 14th, 2016 at $18.01. In approximately 3 months, Boston Scientific has returned 27.60% as of today's recent price of $22.98.
BSX: 22.37 (-0.60)
India Peripheral Vascular Devices Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Medtronic, Boston Scientific, Terumo - Research and Markets
BusinessWire - Fri Jun 10, 10:31AM CDT
Research and Markets has announced the addition of the "India Peripheral Vascular Devices Market Outlook to 2021" report to their offering.
BSX: 22.37 (-0.60), MDT: 83.26 (-2.51)
Global Spinal Cord Stimulation Market Report: 2016 Edition Featuring Medtronic Plc., Nevro Corporation, Boston Scientific, and St. Jude Medical - Research and Markets
BusinessWire - Fri Jun 10, 4:29AM CDT
Research and Markets has announced the addition of the "Global Spinal Cord Stimulation Market Report: 2016 Edition" report to their offering.
BSX: 22.37 (-0.60), MDT: 83.26 (-2.51), NVRO: 70.48 (-3.62)
After Yesterday's Rally of 2.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 09, 12:02PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $22.76 to a high of $23.28. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $22.92 on volume of 11.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 22.37 (-0.60)
Watch for Shares of Boston Scientific (BSX) to Approach Resistance at $23.16
Comtex SmarTrend(R) - Thu Jun 09, 9:22AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today above their pivot of $22.74 and have already reached the first level of resistance at $22.98. Should the shares continue to rise, the resistance pivots of $23.16 and $23.58 will be of interest.
BSX: 22.37 (-0.60)
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 22.37 (-0.60), HAE: 28.76 (-1.41), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40)
Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation
PR Newswire - Wed Jun 08, 5:30PM CDT
Boston Scientific Corporation (NYSE: BSX) today announced a global restructuring program to build on the progress the company has made in executing long-term growth strategies and bringing differentiated value and innovation to patients and healthcare systems. The program is focused on developing global commercialization, technology and manufacturing capabilities in key growth markets, continuing implementation of the company's plant network optimization strategy and expanding operational efficiencies in support of the company's operating income margin goals.
BSX: 22.37 (-0.60)
Hill-Rom: Welch-Allyn Buyout Drives Q2, Forex Woes Stay
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:20AM CDT
Hill-Rom (HRC) posted a mixed second quarter of fiscal 2016 with the bottom line surpassing the Zacks Consensus Estimate and the top line missing the same.
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), HRC: 50.27 (-1.79)
Genomic Health: Can the Liquid Biopsy Test Boost Margins?
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:50AM CDT
Genomic Health (GHDX) recently launched a next-generation sequencing blood-based mutational panel -- Oncotype SEQ Liquid Select.
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), GHDX: 26.11 (-0.48)
GNC Gains as Buyout Rumors of Vitamin Shoppe Resurface
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:32AM CDT
The Vitamin Shoppe buyout rumor first buzzed in immediately after GNC Holdings Inc.'s (GNC) earnings call in the last quarter.
BSX: 22.37 (-0.60), HLF: 57.50 (-4.83), BAX: 43.85 (-2.11), GNC: 24.50 (-1.22)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), QGEN: 21.01 (-1.38)
27.0% Return Seen to Date on SmarTrend Boston Scientific Call (BSX)
Comtex SmarTrend(R) - Mon Jun 20, 1:24PM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on March 14th, 2016 at $18.01. In approximately 3 months, Boston Scientific has returned 27.02% as of today's recent price of $22.87.
BSX: 22.37 (-0.60)
Xtant(TM) Medical Announces Changes to Its Executive Management and Board of Directors
GlobeNewswire - Thu Jun 16, 4:33PM CDT
Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Paul Buckman, Eric Timko, and Rudy Mazzocchi to its Board of Directors. The Company also announced the resignation of Directors Jon Wickwire and David Goodman. The above changes will be effective as of July 2, 2016.
BSX: 22.37 (-0.60), XTNT: 2.00 (-0.05)
Boston Scientific: NICE Backs GreenLight XPS for BPH Cure
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:01AM CDT
As per NICE's estimates, broad adoption of Boston Scientific's (BSX) GreenLight therapy over TURP can lead to savings of up to ??3.2 million annually for the National Health Service (NHS).
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), NUVA: 57.93 (-0.93)
Boston Scientific (BSX) Breaks Through Support at $22.85
Comtex SmarTrend(R) - Tue Jun 14, 9:07AM CDT
Shares of Boston Scientific (NYSE:BSX) have bearishly opened below the pivot of $23.00 today and have reached the first support level of $22.85. Investors may be interested in a cross of the next downside pivot targets of $22.75 and $22.50.
BSX: 22.37 (-0.60)
National Institute for Health and Care Excellence Provides Positive Guidance for Use of Boston Scientific GreenLight XPS(TM) Laser Therapy System in the Treatment of BPH
PR Newswire Europe - Tue Jun 14, 7:30AM CDT
Studies show that treatment is less costly and has lower hospital re-admissions
BSX: 22.37 (-0.60)
Boston Scientific: Restructuring Plan, Global Growth Impress
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 6:14AM CDT
On Jun 13, 2016, we issued an updated research report on Boston Scientific Corporation (BSX).
BSX: 22.37 (-0.60), ICUI: 106.49 (-1.64), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40)
The 3 Top Total Returning Mutual Funds Over The Last 3 Years
Adam Clark - Zacks Investment Research - Mon Jun 13, 3:17PM CDT
These mutual funds have produced the highest total return percentage in the last 3 years, and have the potential to remain atop the top-performing mutual fund list.
BSX: 22.37 (-0.60), ISRG: 644.82 (-16.50), TSLA: 193.15 (-3.25), AMZN: 698.96 (-23.12), MDT: 83.26 (-2.51), LBTYA: 28.80 (-4.34), FB: 112.08 (-3.00), GOOGL: 685.20 (-29.67)
Shares of BSX Up 27.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 1:14PM CDT
SmarTrend identified an Uptrend for Boston Scientific (NYSE:BSX) on March 14th, 2016 at $18.01. In approximately 3 months, Boston Scientific has returned 27.60% as of today's recent price of $22.98.
BSX: 22.37 (-0.60)
India Peripheral Vascular Devices Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Medtronic, Boston Scientific, Terumo - Research and Markets
BusinessWire - Fri Jun 10, 10:31AM CDT
Research and Markets has announced the addition of the "India Peripheral Vascular Devices Market Outlook to 2021" report to their offering.
BSX: 22.37 (-0.60), MDT: 83.26 (-2.51)
Global Spinal Cord Stimulation Market Report: 2016 Edition Featuring Medtronic Plc., Nevro Corporation, Boston Scientific, and St. Jude Medical - Research and Markets
BusinessWire - Fri Jun 10, 4:29AM CDT
Research and Markets has announced the addition of the "Global Spinal Cord Stimulation Market Report: 2016 Edition" report to their offering.
BSX: 22.37 (-0.60), MDT: 83.26 (-2.51), NVRO: 70.48 (-3.62)
After Yesterday's Rally of 2.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 09, 12:02PM CDT
Boston Scientific (NYSE:BSX) traded in a range yesterday that spanned from a low of $22.76 to a high of $23.28. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $22.92 on volume of 11.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BSX: 22.37 (-0.60)
Watch for Shares of Boston Scientific (BSX) to Approach Resistance at $23.16
Comtex SmarTrend(R) - Thu Jun 09, 9:22AM CDT
Shares of Boston Scientific (NYSE:BSX) opened today above their pivot of $22.74 and have already reached the first level of resistance at $22.98. Should the shares continue to rise, the resistance pivots of $23.16 and $23.58 will be of interest.
BSX: 22.37 (-0.60)
Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 22.37 (-0.60), HAE: 28.76 (-1.41), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40)
Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation
PR Newswire - Wed Jun 08, 5:30PM CDT
Boston Scientific Corporation (NYSE: BSX) today announced a global restructuring program to build on the progress the company has made in executing long-term growth strategies and bringing differentiated value and innovation to patients and healthcare systems. The program is focused on developing global commercialization, technology and manufacturing capabilities in key growth markets, continuing implementation of the company's plant network optimization strategy and expanding operational efficiencies in support of the company's operating income margin goals.
BSX: 22.37 (-0.60)
Hill-Rom: Welch-Allyn Buyout Drives Q2, Forex Woes Stay
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:20AM CDT
Hill-Rom (HRC) posted a mixed second quarter of fiscal 2016 with the bottom line surpassing the Zacks Consensus Estimate and the top line missing the same.
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), HRC: 50.27 (-1.79)
